Inside the unconventional FDA panel that could reshape the peptide industry

Source: Business Insider

Peptides are under scrutiny in an FDA meeting running July 23-24Olena Malik/Getty ImagesAn unconventional FDA panel is reviewing peptide safety, focusing on banned therapeutic peptides. The FDA raised concerns over peptide safety, citing immune reactions and a lack of evidence of efficacy. Better access to peptides could open up a multibillion-dollar market for telehealth companies.